Physician profile
Michael S Pad
NPI 1821068529
$1,528.35
in general payments reported to CMS, 2019-2025
13 companies · $417 in 2025
The $417 reported for 2025 was more than what 90% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.15 · 2022: $296 · 2023: $324 · 2024: $455 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,195.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $784.68 | 2022-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $200.26 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Nestle Healthcare Nutrition INC. | $94.11 | 2021-2023 | |
| Lilly USA, LLC | $86.72 | 2024-2025 | Omvoh, Zepbound |
| Ironwood Pharmaceuticals, INC | $86.14 | 2022-2024 | Linzess |
| Aimmune Therapeutics, INC. | $63.00 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.44 | 2022-2024 | Trulance, Plenvu, Xifaxan |
| Abbvie INC. | $50.48 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $38.62 | 2025 | Dupixent |
| Redhill Biopharma INC. | $20.03 | 2022 | |
| Celltrion USA INC. | $15.43 | 2025 | Vegzelma |
| Merck Sharp & Dohme LLC | $15.27 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.17 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.